The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration.
 
Jeremy S. Abramson
Consulting or Advisory Role - Celgene; Genentech/Roche; Gilead Sciences; Novartis; Seagen
Research Funding - Celgene (Inst); genentech (Inst); Millennium (Inst); Seagen (Inst)
 
Tanya Siddiqi
Consulting or Advisory Role - Juno Therapeutics; Pharmacyclics
Speakers' Bureau - Pharmacyclics/Janssen; Seagen
Research Funding - Abbvie (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Maria Lia Palomba
Honoraria - Juno Therapeutics (I)
Consulting or Advisory Role - Merck; Pharmacyclics/Janssen
 
Leo I. Gordon
Patents, Royalties, Other Intellectual Property - Zylem
Other Relationship - Gilead Sciences
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Genentech; Gilead Sciences; Juno Therapeutics; Pharmacyclics; Seagen; TG Therapeutics
 
Jon E. Arnason
Consulting or Advisory Role - Gilead Sciences; Regeneron
 
Michael Wang
Honoraria - Acerta Pharma; Janssen
Consulting or Advisory Role - Acerta Pharma; Janssen; Pharmacyclics
Research Funding - Acerta Pharma; Asana Biosciences; BeiGene; Celgene; Janssen; Juno Therapeutics; Kite, a Gilead company; Novartis
 
Andres Forero-Torres
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)
 
Tina Albertson
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
 
Christine Dehner
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
 
Jacob Garcia
Employment - Amgen; Juno Therapeutics
Stock and Other Ownership Interests - Amgen; Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
Travel, Accommodations, Expenses - Juno Therapeutics
 
Daniel Li
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
Benhuai Xie
Employment - Astellas Pharma (I); Takeda
 
David G. Maloney
Research Funding - Juno Therapeutics (Inst)